Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma - Lin, Chi; Verma, Vivek; Lazenby, Audrey; Ly, Quan P; Berim, Lyudmyla D; Schwarz, James K; Madiyalakan, Madi; Nicodemus, Christopher F; Hollingsworth, Michael A; Meza, Jane L; Are, Chandrakanth; Padussis, James; et al. (American journal of clinical oncology, 2019)
Keywords: Adenocarcinoma - diagnostic imaging; Adenocarcinoma - mortality; Adenocarcinoma - pathology; Adenocarcinoma - therapy; Adult; Aged; Antibodies, Monoclonal, Murine-Derived - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; CA-125 Antigen - blood; Camptothecin - adverse effects; Camptothecin - analogs & derivatives; Camptothecin - therapeutic use; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil - adverse effects; Fluorouracil - therapeutic use; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin - adverse effects; Leucovorin - therapeutic use; Magnetic Resonance Imaging - methods; Male; Membrane Proteins - blood; Middle Aged; Nelfinavir - adverse effects; Nelfinavir - therapeutic use; Neoadjuvant Therapy - methods; Neoplasm Invasiveness - pathology; Organoplatinum Compounds - adverse effects; Organoplatinum Compounds - therapeutic use; Pancreatic Neoplasms - diagnostic imaging; Pancreatic Neoplasms - mortality; Pancreatic Neoplasms - pathology; Pancreatic Neoplasms - therapy; Pancreaticoduodenectomy - methods; Proportional Hazards Models; Radiosurgery - methods; Risk Assessment; Survival Analysis; Time Factors; Tomography, X-Ray Computed - methods; Treatment Outcome